Pre-initiation visit in Prague, for the Phase III trial of Alpha1H in bladder cancer

▤ Summary

Hamlet BioPharma completed a pre-initiation visit in Prague for its Phase III Alpha1H trial in bladder cancer. The company is advancing the study with Professor Marek Babjuk’s team at Charles University, building on a successful Phase II trial. The update highlights the clinical and commercial potential of Alpha1H and its relevance to patients with recurrent non-muscle invasive bladder cancer. The article also notes the FDA’s prior scientific evaluation of the therapy and the ongoing collaboration with Lund University.

▦ Linked Companies